The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share

IAR provides software and services for embedded development used by companies worldwide for creation of secure products. Headquartered in Uppsala, Sweden, IAR has a global presence of sales and support offices worldwide. The shares in IAR are traded on Nasdaq Stockholm, Mid Cap. The offer values IAR at approximately SEK 2,293 million.


Vinge’s team mainly consists of Rikard Lindahl, Erik Sjöman, Joel Magnusson, Benjamin Vafaeian, Louise Nässén and Vilma Henricsson (Capital Markets and Public M&A), Jonas Johansson (M&A), Arvid Weimers, Josefine Lanker, Nour Makie and Katja Häglund (Banking and Finance), Johanna Fjellström and Alice Göransson (Labor Law), Rebecka Målquist and Melinda Oldenburg (IP), Eva Fredrikson, Martin Boström, Siri Blomberg and Filippa Eriksson (Commercial agreements, IT and GDPR), Fredrik Hellström and Lovisa Arpi (FDI), Gulestan Ali (Compliance) and Diana Kanold (VDR).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025